Examining Inflammatory Interstitial Lung Disease from a Drug Development Perspective

8:25 am Chair’s Opening Remarks

8:30 am Registration & Networking

9:00 am Comparing & Contrasting Fibrotic & Inflammatory ILDs in Order to Comprehensively Understand Key Differences in Their Development & Progression & Learning How This Influences Drug Development

  • Cara Williams Vice President & Head of Preclinical Biology: Inflammation & Immunology Research Unit, Pfizer

9:30 am Understanding How to Define Patient Populations, Select Optimal Intervention Points & Outline Clear Therapeutic Outcomes to Streamline the Design & Development of Therapies for Inflammatory ILDs

  • Nina Patel Director – Clinical Development & Medical Affairs ILD, Boehringer Ingelheim

10:00 am Designing Trials for Inflammatory ILDs in 2022 & Beyond: Spotlight on Ssc-ILD

10:30 am Speed Networking

11:00 am Morning Break & Networking

Biomarkers 101: Exploring the Emerging Consensus on Which Biomarker is the Most Useful for ILD Drug Development

11:30 am OSIC Project – Exploring Imaging Based Biomarkers, CT Scans/ Data Collection to Predict FVC Decline

12:00 pm Exploring Biomarkers for Differential Diagnosis of Interstitial Lung Diseases

12:30 pm Lunch & Networking

Revealing Supportive Care & Symptom Management for ILD Treatment

Revealing Supportive Care & Symptom Management for ILD Treatment

1:00 pm Exploring the Impact & Importance of Quality of Life on the Patient Journey

  • Farrell Simon Vice President & Head of US Marketing, Trevi Therapeutics

Exploring Endpoints for Clinical Trials

1:30 pm Devising & Developing Composite Endpoints Which are Realistic & Achievable to Use in Your Next Clinical Trial

  • Peter Fernandes Vice President & Chief Regulatory, Quality & Safety Officer, Bellerophon Therapeutics

2:00 pm Exploring Endpoints in the Context of Inflammatory ILDs: Debating Which Factors You Must Measure to Accurately Assess the Efficacy of Treatment in Inflammatory vs Fibrotic ILDs

  • Elizabeth Renzoni Consultant Respiratory Physician, Honorary Senior Lecturer, Imperial College London

2:30 pm Afternoon Break & Networking

Innovative Imaging for Interstitial Lung Disease

3:30 pm Machine Learning & Interstitial Lung Disease: A Deep Dive

  • Simon Walsh Consultant Thoracic Radiologist, Machine Learning Scientist & Imaging Chair, Imperial College London

Discovering Lumping vs Splitting Through a Wider Lens

4:00 pm Scrutinizing the Practicalities of Deciding When to Lump or Split in the Context of Disease Progression in Order to Inform & Optimize Your ILD Drug Development Strategy

4:30 pm End of Conference Day One